Preclinical biotech developing pancreatic beta-cell modulators for diabetes
| Date | Round | Amount |
|---|---|---|
| May 2023 | Series A DiogenX raised EUR27.5M Series A from Roche Venture Fund, Eli Lilly, Omnes, Boehringer Ingelheim Venture Fund, JDRF T1D Fund and Adbio Partners. | $29.7M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.